ALGS
Aligos Therapeutics, Inc.
$6.73
+0.64 (+10.51%)
At close · Jul 8
Market Cap
$24.29M
Shares
3,587,892
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.73
Open$5.92
Day$5.88–6.93
52W$4.80–13.69
Avg vol 30d227K
Short int612K · 17.0% float · 6.1d
Short vol37%
DataOct 2020–Jul 2026
Filing10-Q · May 7
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−14%
below
Price vs 50-day avg
+18%
above
RSI (14)
68
neutral
MACD trend
Positive
52-week position
22%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+36%
trailing
6-month return
−27%
trailing
YTD return
−28%
this year
Relative strength
−35%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $8 — 200d above 50d
Institutional flow
Flat
1 of 34 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
17.05% of float · ▲ +6.0% MoM · 6.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
34 holders — mid 1-yr range
Squeeze score
74
high risk · 0–100
Fundamentals
Revenue growth
−39%
Y/Y
EPS growth
+88%
Y/Y
Free cash flow
$-82.6M
Balance sheet
$18.3M
net cash
Quant / Vol
risk profile
Volatility
80%
annualized · 1-yr
Max drawdown
−63%
past year
ATR
7.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−14%
Bearish
Price vs 50-day avg
+18%
Bullish
RSI (14)
68
Neutral
MACD trend
Positive
Bullish
52-week position
22%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $6 › 200d $8 — 200d above 50d
Institutional flow
Flat
1 of 34 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
17.05% of float · ▲ +6.0% MoM · 6.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
34 holders — mid 1-yr range
Price context
position in its 52-week range
52-wk low $5
Now $7 · 22%
52-wk high $14
vs 200-day avg -14%
vs 50-day avg +18%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALGS
this stock
Aligos Therapeutics, Inc.
|
$24.29M | -27.8% | -39.5% | — | 17.0% |
|
ONC
BeOne Medicines Ltd.
|
$437.67B | -0.6% | +22179.2% | 890.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.01B | +9.9% | +46.2% | 29.5 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.03B | -14.0% | +20.8% | 16.3 | 3.2% |
|
ARGX
Argenx SE
|
$56.84B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALGS | +16.6% | +35.7% | -27.2% | +16.6% | -27.8% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +16.8% | +34.9% | -34.6% | +16.8% | -37.1% |